A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer.

Name: A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer.
Author: McHugh, Deaglan

A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer. — المؤلف: McHugh, Deaglan — Investigational new drugs 20200323

المؤلف: McHugh, Deaglan
النشر: Investigational new drugs 20200323
الوصف: 1052-1060 p.
الموضوعات: Aged؛ Aged, 80 and over؛ Antibodies, Monoclonal؛ Antineoplastic Agents؛ Follow-Up Studies؛ Humans؛ Male؛ Maximum Tolerated Dose